Guangdong Siji Pharmaceutical

Guangdong Siji Pharmaceutical Co., Ltd. is a pharmaceutical company based in Shantou, China, specializing in the development and commercialization of innovative Traditional Chinese Medicine (TCM). Founded in 2004, the company is best known for its flagship product, Shenyu Ningshen Tablet (参郁宁神片), which was approved by the NMPA in 2023 as a Class 1.1 innovative TCM for the treatment of mild to moderate depression. The company operates under a Marketing Authorization Holder (MAH) model, collaborating with partners like Yili Pharmaceutical for large-scale manufacturing. Its research focus lies in psychiatric and neurological disorders, aiming to modernize traditional herbal therapies through rigorous clinical trials. Guangdong Siji Pharmaceutical's products are included in China's National Reimbursement Drug List, reflecting their clinical value and market significance.